Tarsus Pharmaceuticals (TARS) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.87
- Estimate
- -$1.77
- Surprise
- +50.6%
- Revenue (period 2026-09-30)
- $194.6M
- Score at report (before → after)
- 6.5 → 6.4/10
Revenue source: xbrl.
How the report landed
Tarsus Pharmaceuticals (TARS) reported a narrower loss than forecast — adjusted EPS of -$0.87 against the -$1.77 estimate (a 50.6% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Hold (6.5/10) to Sell at 6.4/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates TARS Sell at 6.4/10.
2 of the last 4 quarters beat the estimate; this quarter's +50.6% surprise compares with a -495.3% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Attractive valuation
What argues against it
- Concentration risk — Product: XDEMVY
- Concentration risk — Supplier: contract manufacturer in Europe
- V7 low-quality RISK_OFF penalty: -0.5 (Q=5.1)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $72.64
- Price target
- $86.03
- Stop
- $67.56
- Upside to target
- +18.4%
- Reward-to-risk
- 2.0:1
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
TARS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $3.40B
- P/E (fwd)
- -145.3
- 52-week range
- $53.89–$91.53
- Off 52-week high
- 20.6%
- RSI (14)
- 51
- Volume vs avg
- 0.83×
- Score today
- 6.4/10